Analytical Data
-
Gene name
MT-RNR2
- Application
-
Alternative Names
MT-RNR2；HN；Humanin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IVG9
-
Expression Region
1-24aa
-
AA Sequence
MAPRGFSCLLLLTSEIDLPVKRRA
-
Molecular Weight
31.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MT-RNR2, a gene encoding the mitochondrial ribosomal protein 2, is essential for mitochondrial protein synthesis and cellular respiration. Research has shown that abnormalities in MT-RNR2 are associated with various mitochondrial diseases, which can lead to severe neurological and muscular disorders. Understanding the functions and mechanisms of MT-RNR2 is crucial for elucidating the pathogenesis of these conditions. Recent advancements in recombinant protein technology have enabled the production of MT-RNR2 in laboratory settings, facilitating the study of its structure and interaction with other mitochondrial components. This research aims to uncover the role of MT-RNR2 in mitochondrial biogenesis and function, as well as its potential implications in therapeutic strategies for mitochondrial disorders. By characterizing MT-RNR2 in a recombinant form, scientists hope to identify novel targets for drug development, paving the way for improved treatments for patients suffering from devastating metabolic disorders linked to mitochondrial dysfunction.
